Symbol="RARE"
AssetType="Common Stock"
Name="Ultragenyx"
Description="Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California."
CIK="1515673"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="60 LEVERONI COURT, NOVATO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="3089637000"
EBITDA="-647024000"
PERatio="None"
PEGRatio="-0.24"
BookValue="3.121"
DividendPerShare="0"
DividendYield="0"
EPS="-9.41"
RevenuePerShareTTM="5.47"
ProfitMargin="-1.873"
OperatingMarginTTM="-1.736"
ReturnOnAssetsTTM="-0.301"
ReturnOnEquityTTM="-1.414"
RevenueTTM="383890000"
GrossProfitTTM="-370780000"
DilutedEPSTTM="-9.41"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.257"
AnalystTargetPrice="91.32"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="9.3"
PriceToBookRatio="6.8"
EVToRevenue="6.79"
EVToEBITDA="-3.744"
Beta="0.865"
num_52WeekHigh="66.29"
num_52WeekLow="33.36"
num_50DayMovingAverage="48.41"
num_200DayMovingAverage="42.87"
SharesOutstanding="70814000"
DividendDate="None"
ExDividendDate="None"
symbol="RARE"
open="44.21"
high="45.00"
low="43.61"
price="44.17"
volume="337116.00"
latest_trading_day="2023-07-13"
previous_close="43.95"
change="0.22"
change_percent="0.5006%"
aroon_positive_momentum_days="58"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="624016"
Change_recent_avg="-0.06"
Delta_recent_avg="1.88"
Variance_recent_avg="0.94"
Change_ratio_recent_avg="-0.16"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="1104"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_negative_thumbnail_id_2="495"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0110.jpeg"
image_neutral_thumbnail_id_1="548"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0051.jpeg"
image_neutral_thumbnail_id_2="543"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0056.jpeg"
image_positive_thumbnail_id_1="1010"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0172.jpeg"
image_positive_thumbnail_id_2="647"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0061.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1168"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
